Accelerating Commercialization in
Nanobiotechnology
Carolina Innovations Seminar
February 3, 2011, 5:30-6:30pm
UNC-Chapel Hill
Brooks Adams, Executive Director
Laura Faulconer, PhD, Director
Jim Roberts, Director
Topics
1. NC COI’s
2. Nanobio opportunity
3. COIN’s role
4. Ways to participate
NC Centers of Innovation / NCBC
Nonprofits creating, organizing & building
targeted biotech-related sectors central to
economic development & job creation in NC
COIs



Recognize unique strengths in NC in specific sectors that
can be catalyzed by focused, collaborative efforts
Assist in tech commercialization by matching industry
needs & resources with focused statewide research
Virtual centers may be regionally located serving
statewide network of partners & collaborators
COIs



Established by academic, industry, economic
development, government consortia
Led by strong inter-university & industrial partners
committed to working collaboratively
Funded COI:
 Medtech
/ Ibiliti: www.ibiliti-nc.org
 Drug Discovery: www.ddcoi.org
 Nanobiotech / COIN: www.nc-coin.org
 Marine Biotech
Nanobio opportunity
“Human health has always been determined on the
nanometer scale…where the structure & properties of
the machines of life work in every one of the cells in
every living thing. The practical impact of
nanosciences on human health will be huge.”
Dr. Richard Smalley, Nobel Laureate, 1943-2005
Nanobiotechnology


Application of nanotech materials, tools, &
processes in the life sciences & medicine
Commercial applications:




Therapeutics & diagnostics
Medical technology & devices
Medical research
Non human health-care related
Nanomedicine
COIN
FOCUS
Cardiac progenitor cell cultures on
PCL nanofibers., Duke University,
Nicolas Christoforu & Kam Leong
Significant federal funding
The promise & challenge

Nanotech/nanobiotech is a tool box not an industry
Frequently represents platform technology
 Many potential high value applications
 Must play into value chain of pharma, biotech, medtech


Nanotech centers are forming globally
Industry clusters growing around them
 Only a few major centers will develop

“A Roadmap for Nanotechnology in NC’s 21st Century Economy,” March 2006
Nanobio global market

2009 nanomedicine market:
N
America $4.75 billion
 Europe $3.65 billion

Emerging nanobio companies:




US 280
Ex-US 150
Hubs in Boston, San Francisco, Houston, & RTP
Significant competition from Asia/China
Sources: Business Insights (Jan 2010), Pew Charitable Trusts, COIN database
Targeted nano-enabled delivery booming
$25

$20

$15

2010 market $6.8 billion 
2015 market $21.1 billion
Drug delivery 97% of market
today  90% by 2015
Other applications:
Cosmeceuticals
 Nutraceuticals
 Ag & food

$10
$5
$0
2010
2011
2012
2013
2014
2015
Source: Lux Research
NC recognized nanotech leader

PEN 2009 survey:
8th in US
 Raleigh metro 4th in US
 NC

Small Times US University Report & Rankings 2009:
 Nanotech
commercialization:
3rd
 UNC-CH 5th
 NCSU
 Nanotech
research: NCSU 10th
NC nanobio


Gaining rapid traction
NC strong in 3 key high growth nanotech sectors:
 Medicine,
biotech, healthcare
 Tools/instruments
 Materials

Positive political-business climate supports biotech:
 NC

Innovation Council
Low-cost of business & high quality of life
NC nanobio ecosystem

Industry




> 35 nanobio & 70 nanotech cos
> 528 bioscience cos
400 medtech cos




35 nano univ research centers
WFIRM
2 nanotech Ph.D. programs
Among 1st with nanotech A.S.
3 major nonprofit research institutes
Medical centers



4 med schools
5 teaching hospitals
Med school forming in Charlotte
Supportive infrastructure



Academic/nonprofit







108 medical products CRO’s
7 major research parks across NC
Active, engaged VCs & angels
NC Commerce
NCBC & Centers of Innovation:
NC Regional Partnerships
Entrepreneur resources




CED, BIG, BREC, other
SBTDC
Southeast TechInventures (STI)
First Flight & univ-based incubators
NC nanobio companies
DRUG DISCOVERY AND DELIVERY
ADVANCED MEDICAL TECHNOLOGY
Asklepios Biopharma
BioDelivery Sciences
Branthan Laboratories
Cromoz
Helia Medical
Liquidia
Micell Technologies
NanIO Biosciences
NanoCor Therapeutics
NanoMed Corp
NanoVector
Peptagen
PharmAgra Laboratories
Qualiber
Salzburg Therapeutics
Thermiacure
Advanced Liquid Logic Morrisville
Biomedomics
Durham
Centice
Morrisville
Dental Safe
Greensboro
Expression Analysis
Durham
Filtara
Cary
Inanovate
Research Triangle Park
Laam Science
Morrisville
NanoArt
Durham
Novan
Research Triangle Park
Nanomics Biosciences
Cary
Pioneer Surgical Orthobio/Greenville
Optotrack
Cary
QuarTek International Greensboro
XinRay Systems
Research Triangle Park
Chapel Hill
Raleigh
Greensboro
Research Triangle Park
Raleigh
Durham
Raleigh
Research Triangle Park
Chapel Hill
Greensboro
Raleigh
Raleigh
Brevard
Chapel Hill
Winston Salem
Greensboro
OTHER
Blue Nano
NanoTech Labs
Specialty Scientific
Xanofi
Cornelius
Yadkinville
High Point
Raleigh
Liquidia Technologies



Developing highly precise particle-based vaccines &
therapeutics for prevention & treatment of human disease
Combining deep understanding of particle-based drug
development with breakthrough small molecule & biological
therapeutics to engineer vaccines & therapies with potential
to dramatically improve quality of human life
Based on PRINT® technology developed in UNC Prof Joe
DeSimone’s lab
Neal Fowler, CEO
Founded 2004
Located in Durham
www.liquidia.com
XinRay


Developing & manufacturing distributed x-ray sources for
a broad range of applications including: Diagnostic
medical, imaging, homeland security, industrial inspection
Carbon nanotube technology derives from core
technologies licensed from UNC-CH & Duke
Moritz Beckmann, CEO
Founded 2007
Located in RTP
www.xinraysystems.com
Qualiber
Developing NanoGTP (gemcitabine triphosphate), a
novel nanoparticle-based treatment for lung,
pancreatic, and other cancers
 Utilize enabling Lipid-Calcium-Phosphate Nanoparticle
drug delivery platform developed in UNC Prof Leaf
Huang’s lab

Anil Goyal, CEO
Founded in 2010
Virtual Company
www.qualiberinc.com
NC univ leaders in nano-enabled drug delivery
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
University Texas
Harvard University
MIT
University of Michigan
Johns Hopkins University
University of Illinois
Northwestern University
University of Washington
Purdue University
University of Utah
GA Institute of Technology
Washington University
University of Florida
University Pennsylvania
Cornell University
Univ of CA at Berkeley
University of Massachusetts
Univ of CA at San Francisco
38.
25.
University of Minnesota
NCI
Rice University
Ohio State University
Univ of CA at Los Angeles
Univ of CA at Santa Barbara
University Nebraska
26.
UNC
27.
University of Wisconsin
45.
Brown University
Penn State University
46.
CALTECH
Massachusetts General Hospital 47.
Arizona State University
University of Kentucky
48.
Columbia University
Stanford University
49.
Rutgers State University
University of Maryland
50.
University of Delaware
University of Southern California
University of Pittsburgh
Source: COIN study 2009;
University of California at Davis
Based on peer-reviewed
Emory University
articles in Web of Science®
SUNY Buffalo
19.
20.
21.
22.
23.
24.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
40.
University of California at San
Diego
Northeastern University
Carnegie Mellon University
41.
NC State University
42.
43.
Vanderbilt University
Case Western Reserve
University
44.
Duke University
39.
Thought leaders in nano drug delivery
UNC-CH
 Leaf Huang
 Joe DeSimone
 Rudolph Juliano
 Wenbin Lin
 Russ Mumper
NCSU
 Nancy MonteiroRiviere
 Roger Narayan
Duke
 Ashutosh Chilkoti
 Kam Leong
Source: COIN study 2009; Based on peer-reviewed articles in Web of Science®
UNC-CH nanobio IP for license
Inventor
Nanoemulsion for small molecule for formulations of drugs and
imaging agents (09-0011)
Russell Mumper
Hybrid Nanoparticles as Dual Therapeutic/Imaging Contrast
Agents (08-0070)
Wenbin Lin
Novel nanoparticle cationic lipids that deliver & enhance
therapeutic activity of siRNA, DNA, and peptides In tumor cells
(08-0038, 08-0049, 08-0134)
Leaf Huang
Tag for siRNA/ Receptor Targeted Oligonucleotides (08-0016)
Rudolph
Juliano
Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
(06-0075)
Wenbin Lin
Methods & compositions comprising cyrstalline nanoparticles of
hydrophobic drugs (08-0080)
Leaf Huang
COIN’s role
Address unmet needs of nanobio community:
 Business intelligence
 Networking & high value connections
 Tech scouting & industry partnering
 Early-stage funding
 Preclinical testing & regulatory guidance
COIN key facts







Nonprofit 501c3 launched June 2009
$2.6 million funds committed
COIN: Economic/business development catalyst advancing
nanobiotech/nanomedicine commercialization
Key asset: Knowledge & network in nanomedicine
Customers: Researchers, entrepreneurs, product
developers, business managers, & investors in nanobiotech
Scope: NC & US
Sustainability: Event sponsors/registrations & member
clients
COIN programs
Premier conference/networking events & workshops
Build, connect, & inform the community…
 Nanobiotech Executive Roundtables
 Annual NC Nanotech Commercialization conference
nanobio/nanomedicine content
NanoBioConnect:
Knowledge-rich web portal providing open access…
 Trusted business intelligence
 Directory/compendium of resources
Innovation services:

Address specific obstacles to commercialization…

Grant writing

Incubation
partners


Connections for pre-clinical testing
Desired end-game commercial outcomes








Licenses
Product concepts move into clinic
Product launches
Funding events
New co formations/growth & co expansions
Job growth
Wealth creation
Tool & service providers achieve financial goals
Accomplishments: Building the organization


First COI funded & launched
4 full-time hires:





Others professional resources:





Brooks Adams  Strategy & program management
Laura Faulconer  Content
Jim Roberts  Connections
Clare Valcore  Logistics
21 university interns to date  Analytics
Outsource finance, marketing, & IT
BOD: 7 outside directors, cross section of nanobio ecosystem
SAB: 7 key thought leaders from academia & industry
New 2400 sq ft HQ, Downtown Durham:


Dedicated collaboration meeting space
Kymanox bullpen for interns & visitors
Some great partners!
Ways to participate: Events
March – NC Nano Commercialization (Charlotte)
May – NanoBio Executive Roundtable (Triangle)
August – MANCEF COMS (Greensboro)
Accomplishments: Events


NCNCC 2010: Nanomed track – 5 speakers/50 attendees
NCNCC 2011:





Roundtables: 3 events, 20 talks, 215 attendees from 8 states
COIN showcasing exhibit: 3 events





Workshop, Nanobio Track, Funding Pitch Room, & Exhibit
21 speakers confirmed (more coming)
2 of 5 pitch room participants signed on
NCNCC (Greensboro)
Medtech (Triangle)
NNI Summit (D.C.)
Talks by COIN staff: Brooks 8, Laura 3, Jim 1
COMS: Recruited with $53K funding commitment secured
When can you get involved?

NC Nanotechnology Commercialization Conference
 March
29-30, 2011
 Charlotte, NC
 COIN nanomedicine workshop morning of March 29
 COIN nanobio track in afternoon March 29
 Conference keynote speakers include
 Travis
Earles, White House Office of Science & Technology
Policy
 Doug Jamison, CEO, Harris & Harris
How and when can you get involved?








MANCEF COMS, based in New Mexico
August 28th, 2011
500-700 people
45% international participation
NCBC, RTI, NC Commerce, Joint School of Nano
Lockheed Martin (energy)
Most federal granting organizations
Norway 2012
Ways to participate: Media &
NanoBioConnect
Raising the profile together

Raise profile of our community & our accomplishments:
press releases  8 to date, more in pipeline
 Strong media partnerships  LTW, TJS, MedCity News,
Nanomedicine Journal
 Routine coverage  LocalTechWire, TechJournal South,
Triad Business Journal, Business NC, NanotechNow, AZO
Nano, Nanowerk, NC Commerce Newsletter
 Thought leadership  White papers & articles for
technical & scientific journals
 Routine

Joint press releases with community
NanoBioConnect

Web-based portal for business intelligence & open
innovation in nanomedicine
 Profiles
of companies, university centers, research
institutes
 Profiles of service providers with nano expertise
 Interview with key thought leaders
 White papers and reports
 Candidate portal

Launched January 2011 with NC-coverage, rapidly
growing to US coverage
Accomplishments: Web/social media

NanoBioConnect:

Since soft launch November:







1,866 visitors , 1,047 unique visitors
8,630 page views, 4.62 pages/visit
5:24 min average
52.09% new visitors
At least a hit from every continent; Most from US, Canada, India, UK
Most popular: homepage, NanoBioConnect, about us, community
January full launch with press release:

Profiles:







29 coos (Plus 8 in QC, 85 in preparation draft)
5 people
1 research institute
19 service providers
White papers & reports: 4
Newsletters: 1
Social media/web:

5 venues  companies, LinkedIn, Twitter (300 followers!), YouTube, Wikipedia
NanoBioConnect next goal

Develop a robust listing of preclinical testing and
contract R&D resources with expertise in nano with
national coverage
NC resources for pre-clinical testing
synthesis
• WFU Nanotech Center
• Nanotech Labs (Yadkinville, NC)
Characte • WFU Nanotech Center, JSNN, Forsyth Tech, Murdoch
rization
In Vitro
In Vivo
Clinical
Trials
• Murdoch, Biomedical Innovation Network, JSNN, ECU, RTI
• Murdoch, Biomedical Innovation Network, JSNN, UNC . RTI
• Duke, UNC, WFU , ECU med schools
• RTI, CROs
UNC Translational Oncology & Nanoparticle Drug Development
Initiative Lab & GLP Bioanalytical Facility

Part of UNC Eshelman School of Pharmacy, UNC Lineberger
Comprehensive Cancer Center, & Carolina Center of Cancer
Nanotechnology Excellence:



An analytical chemistry & pharmacology lab focusing on pharmacologic
characterization & translational development of small molecule &
nanoparticle anticancer agents
Has unique methods & technologies fundamental to development of
nanoparticle agents
Performs formulation, stability, efficacy, toxicity, phenotypic probe,
pharmacokinetic & pharmacodynamic studies of nanoparticle agents
Bill Zamboni, Director
Founded 2009
Located in Chapel Hill
http://www.unclineberger.org/research/cores/facility.asp?facilityID=3
Ways to participate: Grant writing services
Grants to accelerate translation

COIN offers grant-writing & other services to
accelerate technology translation and development
grant-writing  Nominal hourly rate with
significant savings over traditional agency
 Partnership to submit grants
 Assistance identifying grant opportunities
 Assistance identifying collaborators
 Support of grants  Letters of support, commitment
 Southeast TechInventures partnership
 Contract
Summary
COIN offers



Innovators & entrepreneurs:
Resources to build relationships crucial for technology
translation & business development
Industry partners:
Single point of entry to nanobiotech sectors in NC and
access to innovators & entrepreneurs
Service providers:
Resources to develop nanobiotech project pipeline
Summary





Market opportunity is apparent but not without
challenges
NC has the assets to continue to be a major player in
nanobio
COIN can and will play on the state & national stages
COIN is coalescing the nanobio community focusing on
key issues
Together we can accelerate commercialization in
nanobiotechnology
The Venable Center
303 S Roxboro St., Ste 30, Durham, NC 27701
Office: (919) 680-2070
Fax: (919) 680-2906
www.nc-coin.org
www.linkedin.com/companies/
coin-center-of-innovation-for-nanobiotechnology
@NCNanoBioTech